5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

作者：Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus, Giuseppe Curigliano, Matti Aapro, Fabrice André, C.H. Barrios, Jonas C. S. Bergh, G.S. Bhattacharyya, Laura Biganzoli, Frances M. Boyle, Maria João Cardoso, L.A. Carey, Javier Cortés, Nagi S. El Saghir, Mona Elzayat, Alexandru E. Eniu, Lesley J. Fallowfield, Prudence A. Francis, Karen A. Gelmon, Joseph Gligorov, Renate Haidinger, Nadia Harbeck, Xin Hu, Bella Kaufman, Rajneesh Kaur, Belinda Emma Kiely, S.-B. Kim, NU Lin, Shirley A. Mertz, Silvia P. Neciosup, B.V. Offersen, Shinji Ohno, Olivia Pagani, Andrés Prat, Frederique Madeleine Penault-Llorca, Hope S. Rugo, George W. Sledge, Christoph Thomssen, D.A. Vorobiof, Theresa Wiseman, Binghe Xu, Larry Norton, A. Costa, Eric P. Winer · 发表于：Annals of Oncology · 年份：2020 · DOI：10.1016/j.annonc.2020.09.010 · 被引用次数：1397 · 研究领域：Advanced Breast Cancer Therapies、Breast Cancer Treatment Studies、Cancer-related Molecular Pathways

For the purpose of advanced breast cancer (ABC) guidelines, ABC comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).1,2 Advanced/metastatic breast cancer remains a virtually incurable disease, with a median overall survival (OS) of about 3 years and a 5-year survival rate of around 25%,3,4 even in countries without major accessibility problems. Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-positive ABC.